Neuroprotection by pyrroloquinoline quinone (PQQ) in reversible middle cerebral artery occlusion in the adult rat

Brain Research

Volumn 1094, Issue 1, 2006, Pages 200-206

  Zhang, Yonghua ^a   Feustel, Paul J ^a,b   Kimelberg, Harold K ^a,b  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Cerebral ischemia; Neuroprotection; Pyrroloquinoline quinone (PQQ); Rat; Reversible middle cerebral artery occlusion

Indexed keywords

PYRROLOQUINOLINEQUINONE; TRIPHENYLTETRAZOLIUM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; HISTOLOGY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; STAINING; STATISTICAL SIGNIFICANCE; SUTURING METHOD;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN INFARCTION; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIC ATTACK, TRANSIENT; MALE; MOLECULAR STRUCTURE; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PQQ COFACTOR; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; TIME FACTORS;

ANIMALIA;

EID: 33745255091     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.03.111     Document Type: Article

References (30)

1. Aizenman E., Hartnett K.A., Zhong C., Gallop P.M., and Rosenberg P.A. Interaction of the putative essential nutrient pyrroloquinoline quinone with the N-methyl-d-aspartate receptor redox modulatory site. J. Neurosci. 12 (1992) 2362-2369
2. Alexandrova M.L., and Bochev P.G. Oxidative stress during the chronic phase after stroke. Free Radical Biol. Med. 39 (2005) 297-316
3. Bishop A., Gallop P.M., and Karnovsky M.L. Pyrroloquinoline quinone: a novel vitamin?. Nutr. Rev. 56 (1998) 287-293
4. Choi D.W., and Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13 (1990) 171-182
5. Corbett D., Hamilton M., and Colbourne F. Persistent neuroprotection with prolonged postischemic hypothermia in adult rats subjected to transient middle cerebral artery occlusion. Exp. Neurol. 163 (2000) 200-206
6. Davidson V.L. Electron transfer in quinoproteins. Arch. Biochem. Biophys. 428 (2004) 32-40
7. Eliasson M.J., Huang Z., Ferrante R.J., Sasamata M., Molliver M.E., Snyder S.H., and Moskowitz M.A. Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neural damage. J. Neurosci. 19 (1999) 5910-5918
8. Gallop P.M., Henson E., Paz M.A., Greenspan S.L., and Fluckiger R. Acid-promoted tautomeric lactonization and oxidation-reduction of pyrroloquinoline quinone (PQQ). Biochem. Biophys. Res. Commun. 163 (1989) 755-763
9. Gallop P.M., Paz M.A., Fluckiger R., and Kagan H.M. PQQ, the elusive coenzyme. Trends Biochem. Sci. 14 (1989) 343-346
10. Gallop P.M., Paz M.A., Fluckiger R., and Henson E. Is the antioxidant, anti-inflammatory putative new vitamin, PQQ, involved with nitric oxide in bone metabolism?. Connect. Tissue Res. 29 (1993) 153-161
11. Garcia J.H., Wagner S., Liu K.F., and Hu X.J. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke 26 (1995) 627-634
12. He K., Nukada H., Urakami T., and Murphy M.P. Antioxidant and pro-oxidant properties of pyrroloquinoline quinone (PQQ): implications for its function in biological systems. Biochem. Pharmacol. 65 (2003) 67-74
13. Jensen F.E., Gardner G.J., Williams A.P., Gallop P.M., Aizenman E., and Rosenberg P.A. The putative essential nutrient pyrroloquinoline quinone is neuroprotective in a rodent model of hypoxic/ischemic brain injury. Neuroscience 62 (1994) 399-406
14. Killgore J., Smidt C., Duich L., Romero-Chapman N., Tinker D., Reiser K., Melko M., Hyde D., and Rucker R.B. Nutritional importance of pyrroloquinoline quinone. Science 245 (1989) 850-852
15. Kimelberg H.K., Feustel P.J., Jin Y., Paquette J., Boulos A., Keller Jr. R.W., and Tranmer B.I. Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion. NeuroReport 11 (2000) 2675-2679
16. Longa E.Z., Weinstein P.R., Carlson S., and Cummin R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20 (1989) 84-91
17. Meldrum B., and Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11 (1990) 379-387
18. Murase K., Hattori A., Kohno M., and Hayashi K. Stimulation of nerve growth factor synthesis/secretion in mouse astroglial cells by coenzymes. Biochem. Mol. Biol. Int. 30 (1993) 615-621
19. Paz M.A., Fluckiger R., Torrelio B.M., and Gallop P.M. Methoxatin (PQQ), coenzyme for copper-dependent amine and mixed-function oxidation in mammalian tissues. Connect. Tissue Res. 20 (1989) 251-257
20. Salisbury S.A., Forrest H.S., Cruse W.B., and Kennard O. A novel coenzyme from bacterial primary alcohol dehydrogenases. Nature 280 (1979) 843-844
21. Sanchez R.M., Wang C., Gardner G., Orlando L., Tauck D.L., Rosenberg P.A., Aizenman E., and Jensen F.E. Novel role for the NMDA receptor redox modulatory site in the pathophysiology of seizures. J. Neurosci. 20 (2000) 2409-2417
22. 14C]pyrroloquinoline quinone in mice. Proc. Soc. Exp. Biol. Med. 197 (1991) 27-31
23. Steinberg F.M., Gershwin M.E., and Rucker R.B. Dietary pyrroloquinoline quinone: growth and immune response in BALB/c mice. J. Nutr. 124 (1994) 744-753
24. Stites T.E., Mitchell A.E., and Rucker R.B. Physiological importance of quinoenzymes and the O-quinone family of cofactors. J. Nutr. 130 (2000) 719-727
25. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 (1999) 2752-2758
26. Urakami T., Yoshida C., Akaike T., Maeda H., Nishigori H., and Niki E. Synthesis of monoesters of pyrroloquinoline quinone and imidazopyrroloquinoline, and radical scavenging activities using electron spin resonance in vitro and pharmacological activity in vivo. J. Nutr. Sci. Vitaminol. (Tokyo) 43 (1997) 19-33
27. Yamaguchi K., Sasano A., Urakami T., Tsuji T., and Kondo K. Stimulation of nerve growth factor production by pyrroloquinoline quinone and its derivatives in vitro and in vivo. Biosci. Biotechnol. Biochem. 57 (1993) 1231-1233
28. Zhang Y., and Rosenberg P.A. The essential nutrient pyrroloquinoline quinone may act as a neuroprotectant by suppressing peroxynitrite formation. Eur. J. Neurosci. 16 (2002) 1015-1024
29. Zhang Y., Jin Y., Behr M.J., Feustel P.J., Morrison J.P., and Kimelberg H.K. Behavioral and histological neuroprotection by tamoxifen after reversible focal cerebral ischemia. Exp. Neurol. 196 (2005) 41-46
30. Zhu B.Q., Zhou H.Z., Teerlink J.R., and Karliner J.S. Pyrroloquinoline quinone (PQQ) decreases myocardial infarct size and improves cardiac function in rat models of ischemia and ischemia/reperfusion. Cardiovasc. Drugs Ther. 18 (2004) 421-431